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ABSTRACT 
We aimed to compare the therapeutic effects of topical 1% sodium hyaluronate (Healon) or hydroxypropyl methylcellulose 
(HPMC) for the treatment of alkali-induced epithelial corneal defects. An alkali burn was produced in 30 corneas of 30 New 
Zealand White rabbits, using a 7.5-mm-diameter trephine. The rabbits were randomly divided into three groups. Four times 
a day, one group was treated with 1% sodium hyaluronate, one with HPMC, and one (the control group) with physiologic 
saline. During the treatment period, the size of the epithelial defect was observed every day, up to day 17, using a slit-lamp 
biomicroscope (with fluorescein). Sodium hyaluronate significantly accelerated the wound healing process compared with 
saline and increased the healing rate to an even greater extent compared with HPMC. Sodium hyaluronate, but not HPMC, is 
an effective wound-healing adjuvant for alkali-induced corneal epithelial defects. 
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INTRODUCTION 
The cornea is a transparent and flat layer of the eye that 
allows light to pass through to reach the inside of the 
eye. The transparent corneal epithelium prevents any 
damage to the lower layers of the cornea by acting as a 
barrier against microorganisms. Any damage to this layer 
may affect its transparency and reduce its protective 
capacity (1, 2). Corneal epithelial defects are a relatively 
common ocular condition, and attempts to treat these 
defects are considered to be a major goal of ophthalmic 
research. The mechanism for repairing and rebuilding the 
corneal epithelium is very similar to the mechanism 
involved in other mucosal layers, and it includes the 
migration and proliferation of epithelial cells. It is 
believed that when damage to the epithelium occurs, 
limbal stem cells migrate towards the center of the 
damage and proliferate rapidly, thereby filling the 
damaged area with new cells (3-5). Various factors can 
influence the healing of epithelial defects, including the 
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presence of growth factors, umbilical cord serum, and 
autologous serum (6-10), the cell migration rate, and the 
rate of desmosome production between the epithelial 
cells. Sodium hyaluronate is a viscoelastic substance that 
is widely used to treat ocular conditions. It is a 
mucopolysaccharide found naturally in vitreous humor 
and synovial fluid, where it acts as a “tissue cement” (11-
15). Hydroxypropyl methylcellulose (HPMC) is also a 
viscoelastic polymer that can be synthesized from 
cellulose. It has been proposed that sodium hyaluronate 
may be a useful treatment for epithelial defects because 
it increases cell migration and the number of 
hemidesmosomes (which attach cells to the extracellular 
matrix). Several studies have been conducted in this 
area, but none has decisively confirmed this theory (16-
19). 
A 2004 study by Gomes et al. showed that human 
corneal epithelial cell in sodium hyaluronate-enriched 
medium exhibited significantly increased migration 
compared with cells in HPMC-enriched medium. 
Promotion of cell migration can subsequently lead to 
rapid wound closure (8). In addition, a 2013 study by Wu 
et al. showed that sodium hyaluronate can protect 
corneal epithelial cells from alkali burns and promote 
healing of corneal epithelial tissue (7). The authors also 
showed that the molecular weight of sodium hyaluronate 
is a crucial factor in determining its effects, and only 
high-molecular-weight sodium hyaluronate significantly 
reduced NaOH-induced cytotoxic effects in corneal cells 
and increased their migration and wound healing ability 
(7). A recent study by  Zhong et al. evaluated the effects 
and mechanism of action of sodium hyaluronate in the 
promotion of corneal epithelial wound healing, and it 
showed that sodium hyaluronate enhanced wound 
healing by promoting cell migration, upregulating repair 
responses, and suppressing inflammatory responses (14). 
In 1998, in a similar study in South Korea, the use of 1% 
sodium hyaluronate (Healon) four times a day to treat a 
5.5-mm-diameter corneal epithelial defect was shown to 
promote a higher recovery rate compared to the control 
treatment (phosphate-buffered saline). This is likely to 
have been due to the higher number of 
hemidesmosomes bonds involving the basement 
membrane layer (14, 15). Thus, the present study was 
designed to test whether 1% sodium hyaluronate could 
be a useful treatment for epithelial defects.  
MATERIALS AND METHODS 
The study involved 30 homogeneous rabbits (New 
Zealand White rabbits of the same aged 6 months, 
weighing 2.0–2.5 kg, which were provided by the Razi 
Institute, Iran). The rabbits were randomly divided into 
three groups, each consisting of 10 rabbits. Corneal alkali 
burns were produced in accordance with the method 
devised by Ormerod et al., with some modifications that 
have been described previously, which are described 
below (16). Briefly, the study was conducted in 
accordance to the principles of double-blind clinical trial, 
and the rabbits were injected intramuscularly with 
sedatives (37.5 mg kg
-1
 ketamine and 10 mg kg
-1
 
xylazine). Local anesthesia was achieved using 0.5% 
tetracaine eyedrops (SinaDarou, Tehran, Iran 
Anestocaine®). Subsequently, an 8-mm epithelial defect 
was produced at the center of the left cornea of each 
rabbit using a 7.5-mm-diameter trephine along with 0.4 
mL of 1 M NaOH for 35 s. The damaged site was then 
rinsed with 20 mL of 0.9 M saline. As the study was 
conducted in sterile conditions, there was no need to use 
antibiotic drops. To decrease bias, we excluded rabbits 
with defects > 8 mm and those with an unusual pattern 
of corneal surface disruption (such as infection or 
perforation) before starting the treatment and more 
rabbits added to each group up to 10. The treatments 
and assessments of the defects began the following day. 
Four times a day, one group was treated with 1% sodium 
hyaluronate, one was treated with HPMC, and the 
control group was treated with physiologic saline. The 
treatments continued until the epithelial defects were 
completely healed. The researcher who administered the 
treatments and the researcher in charge of assessing the 
defects in the rabbits were both blinded to the treatment 
groups (i.e., the treatments were labelled with numbers 
rather than their names). 
 We used a slit-lamp biomicroscope (HAAG-STREIT AG, 
Bern, Switzerland) to assess the defects. Fluorescein (an 
orange dye) was used in order to ensure that stimulation 
of the cornea and conjunctiva and epithelial infections 
could be easily discerned. The decrement of the defect 
diameter and corneal improvement was measured 
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during the assessments. To measure the size of each 
defect, the slit-lamp biomicroscope was used to measure 
the largest diameter of the defect (i.e., when the width 
of light from the device became increasingly thin slit size) 
in millimeters.  
 
 
Figure 1. Slit-lamp photographs of the cornea of a 
representative rabbit in the group treated with 1% topical 
sodium hyaluronate (Healon) on days 1, 2, 4, 7, and 14 
 
Each rabbit was checked once a day until the defect was 
completely healed. To provide representative 
documentation of the healing process, one rabbit was 
chosen from each group, and four color photographs of 
the epithelial defect were taken on days 1, 2, 4, and 7 
during the treatment, as shown in Figure 1 for the rabbits 
in the sodium hyaluronate group. After each assessment, 
the data were recorded. SPSS version 16 (SPSS Inc., 
Chicago, IL, USA) was used to analyze the data. The 
between-group differences in the mean sizes and the 
number of days to compete recovery were tested using 
XYZ tests, and P values < 0.05 were considered 
significant. At the end of the experiment, the treatment 
groups were disclosed, and the results were interpreted. 
This study was conducted in accordance with the 
provisions set out in the Statement for the Use of 
Animals in Ophthalmic and Visual Research from the 
Association for Research in Vision and Ophthalmology, 
and with respect to the care committee and animal use 
in Ophthalmology Research (ethical approval number 
426_T). The techniques used were selected in order to 
cause the least amount of pain (and other stimulation) 
possible to the animals. Before injuring each cornea, we 
anesthetized the area using tetracaine. If an assessment 
was difficult due to a rabbit’s movement, the rabbit was 
injected with 37.5 mg kg
-1
 ketamine. Only one eye of 
each animal was injured, so as to disrupt their natural 
lives as little as possible. 
RESULTS 
The following mean epithelial defect diameters (± SD) 
were measured on day 1:    ± 7.46 mm2 for the sodium 
hyaluronate group, 37.1 ± 6.45 mm
2
 for the HPMC group, 
and 39.1 ± 8.17 for the control group. There were not 
significant differences in the sizes on day 1 (P = 0.794) 
(Table 1). 
On day 2, there was a significant reduction in the mean 
diameter of the epithelial defects compared to day 1 (in 
both statistical and clinical terms) for all groups (P < 
0.05), to 15 ± 1.12, 16.5 ± 7.62, and 23.8 ± 1.47 mm
2 
for 
the groups treated with sodium hyaluronate, HPMC, and 
saline,
 
respectively. However, even on day 2, the 
between-group differences in the size of epithelial 
defects were not significant (P = 0.21) (Table 1). 
As shown in Figure 2, the improvement in the rabbits in 
the sodium hyaluronate group increased considerably 
after day 2, though minor increases in the size of the 
epithelial defect were observed on days 5 and 6. Full 
recovery was observed in this group on day 11 (Table 2). 
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Table 1. Comparison of the size of the corneal epithelial defects in all three groups on day 1 to 8 of treatment 
HPMC, hydroxypropyl methylcellulose; SD: standard deviation 
 
Figure 2. Size of corneal epithelial defect by day of treatment in the 1% sodium hyaluronate (Healon) group 
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 Days 
Groups 1 2 3 4 5 6 7 8 
1% sodium hyaluronate (Healon)         
Mean 39.0 15.0 4.78 1.52 2.6 3.52 1.32 1.07 
SD 7.468 1.127 4.004 2.44 2.63 3.24 1.22 1.65 
HPMC         
Mean 37.1 16.5 18.0 13.2 5.6 4.4 3.9 5.15 
SD 6.454 7.619 8.47 7.06 3.89 2.5 3.66 9.092 
Control (saline)         
Mean 39.1 23.8 21.0 19.9 15.4 10.6 12.2 15.4 
SD 8.17 1.47 7.19 4.75 6.83 5.168 7.004 1.265 
P value 0.8 0.2 0.0001 0.0001 0.0001 0.0001 0.0001 0.004 
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As shown in Figure 3, there was a relatively steady 
decrease in the size of the epithelial defect in the HPMC 
group, though minor increases in the size were observed 
on days 8 and 10. However, there was quick recovery 
from day 11 (Table 2). Full recovery was observed by day 
17 (Table 2). Despite the difference in the rate of healing 
between the groups, the degree of corneal opacity was 
almost the same after complete healing of the defects. 
The results for the control group are shown in Figure 4. 
There was a relatively steady recovery, with minor 
increases in the size of the epithelial defect on days 7 and 
8, which improved quickly thereafter. Full recovery 
occurred by day 15 (Table 2). Figure 5 shows a between-
group comparison of the improvement in the size of the 
corneal epithelial defects over time. 
 
 
 
Table 2. Comparison of the size of the corneal epithelial defects in all three groups on day 8 to 17 of treatment 
Group Day 
 9 10 11 12 13 14 15 16 17 
1% sodium hyaluronate (Healon)          
Mean 0.25 0.05 0 0 0 0 0 0 0 
SD 0.408 0.105 0 0 0 0 0 0 0 
HPMC          
Mean 4.4 5.3 3.6 3.0 2.8 2.5 1.3 0.4 0 
SD 7.5 8.92 5.93 6.13 1.3 1.22 0 0 0 
Control (saline)          
Mean 11.9 11.9 8.5 7.9 3.2 1.3 0 0 0 
SD 1.04 1.3 1.027 1.078 1.54 1.1 0 0 0 
P value 0.006 0.025 0.033 0.061 0.64 0.32 0.001 0.01 0 
HPMC, hydroxypropyl methylcellulose; SD: standard deviation 
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Figure 3. Size of corneal epithelial defect by day of treatment in HPMC group 
HPMC, hydroxypropyl methylcellulose 
 
 
Figure 4. Size of corneal epithelial defect over time in the control group 
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Figure 5. Comparison of the size of corneal epithelial defects in all three groups by day of treatment 
HPMC, hydroxypropyl methylcellulose 
 
DISCUSSION
This study was conducted in accordance with the 
principles of double-blind clinical trials, and it involved 
the use of a trephine to make identical epithelial defects 
in order to prevent potential biases between the three 
treatment groups (i.e., there was no significant between-
group difference in the epithelial defects at the beginning 
of the experiment). Corneal epithelial defects are 
common in both industrial and non-industrial societies, 
and patients with this condition constitute a considerable 
proportion of cases presenting at optometrists’ clinics. 
Shortening the treatment duration for patients with 
epithelial defects (irrespective of the causes of the 
wounds) would result in less morbidity; a lower 
likelihood of side effects associated with the wound, and 
increased quality of life. It would also reduce the 
productivity losses caused by the long recuperation 
period for patients, their families, wider society, 
employers, and insurance companies. Therefore, it is 
clear that developing treatments that shorten the 
treatment duration is a priority for medical researchers 
and health services. Reducing the treatment duration is 
particularly important for patients with corneal epithelial 
damage because, as the cornea has no blood vessels, it 
has less potential for recovery compared to other tissues. 
This further leads to an increased risk of infection, 
development of corneal opacity, and scarring if the 
cornea is subject to long-term epithelial defects, which 
can result in permanent visual impairment or blindness. 
In addition to its important role in refraction, the cornea 
also acts as one of the most important protective barriers 
in the visual system, so increasing the rate of recovery 
from corneal damage, even by one day, is of great 
importance (9, 17-22). 
The epithelial defects in the rabbits treated with sodium 
hyaluronate were completely healed in < 11 days. The 
results of this study concur with those of a study by Wu 
CL et al., which concluded that 1% sodium hyaluronate 
increased the epithelial defect recovery rate (7). 
However, interestingly, in a 1989 study in Sweden by 
Chung et al 1% and 2% sodium hyaluronate did not 
decrease the epithelial defect recovery rate (9). The 
results of our study and the study by Wu CL et al. appear 
to support those of studies such as a study by Gomes et 
al. (8) and a study in Israel by Steiebel-Kalish based on 
animal models (10). It appears that the high recovery 
rates might be the result of fewer inflammatory cells 
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(such as polymorphonuclear cells) in the corneal stroma 
and more keratocysts. As the results indicate, although 
the rabbits treated with HPMC and saline fully recovered, 
the treatment duration in the HPMC group was 17 days, 
and that in the control group was 15 days. In comparison, 
the treatment duration in the sodium hyaluronate group 
was 11 days, and the between-group differences were 
statistically significant. Although 1% sodium hyaluronate 
has one-fourth the volume and three times the cost of 
HPMC, it appears to be a useful treatment for corneal 
epithelial defects, as it statistically and clinically 
significantly reduced the treatment duration in rabbits. In 
addition, 1% sodium hyaluronate may be especially 
useful for treating patients for whom treatments with 
artificial tears (such as HPMC-based eyedrops) and saline 
have failed. The fact that the treatment duration with 
HPMC is longer than that associated with saline indicates 
that HPMC should not be used to treat corneal epithelial 
defects. 
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